Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oragenics Inc (NY: OGEN )

1.070 -0.200 (-15.75%)
Official Closing Price Updated: 8:00 PM EDT, Sep 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 131,236
Open 1.230
Bid (Size) 1.040 (1)
Ask (Size) 1.050 (2)
Prev. Close 1.270
Today's Range 1.060 - 1.230
52wk Range 0.8611 - 7.740
Shares Outstanding 5,580,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Completes Manufacture, Filling of Intranasal Device for Use in Upcoming Clinical Trial
Via Investor Brand Network
EXCLUSIVE: Oragenics Completes Spray Dry Drug Manufacturing, Intranasal Device Filling For Anticipated Mid-Stage Study For Patients With Brain Injury
Oragenics completes the formulation and filling of its nasal spray drug, ONP-002, for concussion treatment, aiming to launch a Phase 2a trial. 
Via Benzinga

Performance

YTD
-84.22%
-84.22%
1 Month
+19.37%
+19.37%
3 Month
-47.29%
-47.29%
6 Month
-25.69%
-25.69%
1 Year
-65.81%
-65.81%

More News

Read More
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Reports on Status of Lead Drug Candidate Designed to Treat Concussion
Via Investor Brand Network
Exposures Product Safety
“Explosive Growth Stocks: Innovations, Strategy, Earners Unlock Prime Potential CXAI, OGEN, PRSO, INBS, KAVL”
Via AB Newswire
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
OGEN Stock Earnings: Oragenics Reported Results for Q2 2024
Via InvestorPlace
OGEN Stock Earnings: Oragenics Reported Results for Q4 2023
Via InvestorPlace
Why Oragenics (OGEN) Shares Are Falling
Via Benzinga
OGEN Stock Earnings: Oragenics Reported Results for Q1 2024
Via InvestorPlace
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032
Via FinancialNewsMedia
EXCLUSIVE: Oragenics' Concussion Drug Clears FDA-Required Cardiotoxicity Testing, Planning For Phase Trials Underway
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Nasdaq Falls Over 100 Points; TJX Posts Upbeat Q1 Results
Via Benzinga
Why XP Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Gold Down Over 1%; Williams-Sonoma Posts Strong Earnings
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Files 10K and Provides Company Update
From Oragenics, Inc.
Via Business Wire
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
From Oragenics, Inc.
Via Business Wire
Oragenics Announces Closing of Public Offering
From Oragenics, Inc.
Via Business Wire
S&P 500 Edges Lower; ADT Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.